Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Emergency Approval of Ebola Test Suggests Opportunity for Test Makers

By LabMedica International staff writers
Posted on 06 Oct 2014
The emergency approval of a real-time PCR test for Zaire Ebolavirus demonstrates the scope of concern about the recent epidemic and a possible opportunity for test makers. More...
The biennial study of the microbiology test product market, “The World Market for Infectious Disease Diagnostic Tests,” by Kalorama Information (New York City, NY, USA) estimated the world market for infectious disease tests at USD 5.3 billion in 2013 and expected it to grow at a slightly higher rate than the rest of the diagnostics market. The scourge of expanding infectious disease threats is part of the factor driving growth of tests. Partly due to the nature of the illness and the high mortality rate (often close to 90% in underdeveloped countries), Ebolavirus disease (EVD) outbreaks can get special international attention from the healthcare community.

Kalorama released its 2013 infectious disease market estimates as the United States Food and Drug Administration (FDA) announced emergency-use-authorization of a TaqMan-based test used by the Department of Defense (DOD). The test was made by the DOD, but is run on instruments from Thermo Fisher Scientific, originally from Carlsbad-based Life Technologies, bought by Thermo Fisher in February 2014. Results of the test, which analyzes blood samples, are available in about 2 hours, whereas other tests take days.

This rare type of emergency authorization by the FDA bypasses the agency's usual approval process. Usually this type of approval is issued during crises, like the current Ebola outbreak in West Africa. "Infectious disease is not an area where governments feel comfortable waiting for test results," said Bruce Carlson, publisher of Kalorama Information, "It's an opportunity for innovative technologies, and test makers who develop solutions in infectious diseases can benefit from the high priority placed on them by healthcare systems."

The Kalorama report covers standard tests for infectious disease, and has breakouts for test technologies and disease categories. Significant efforts in microbiology are detailed in company profiles.

Related Links:

Kalorama Information
The World Market for Infectious Disease Diagnostic Tests 
US FDA Emergency-Use-Authorization of test for Ebola Zaire Virus



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.